Balyasny Asset Management LLC Cti Biopharma Corp Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $3.88 Million - $5.38 Million	871,409 New	871,409 $5.24 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $206,599 - $364,895	58,197 Added 131.86%	102,333 $611,000
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $83,858 - $230,831	44,136 New	44,136 $206,000
Q2 2019 Aug 14, 2019	SELL	$0.8 - $1.03 $174,618 - $224,821	-218,273 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$0.9 - $1.37 $633,943 - $965,003	-704,382 Reduced 76.34%	218,273 $212,000
Q4 2018 Feb 14, 2019	BUY	$0.73 - $2.19 $454,538 - $1.36 Million	622,655 Added 207.55%	922,655 $677,000
Q3 2018 Nov 14, 2018	SELL	$1.72 - $5.24 $22,215 - $67,679	-12,916 Reduced 4.13%	300,000 $648,000
Q2 2018 Aug 14, 2018	BUY	$3.81 - $5.26 $1.19 Million - $1.65 Million	312,916 New	312,916 $1.56 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.